<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00020176</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067899</org_study_id>
    <secondary_id>NCI-00-C-0119</secondary_id>
    <secondary_id>NCI-1027</secondary_id>
    <nct_id>NCT00020176</nct_id>
    <nct_alias>NCT00005568</nct_alias>
  </id_info>
  <brief_title>Allogeneic Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer</brief_title>
  <official_title>Allogeneic Breast Protocol 1: T-Cell Depleted Allogeneic Blood Stem Cell Transplantation Using an Immunoablative Conditioning Regimen in Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were&#xD;
      destroyed by chemotherapy used to kill tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of allogeneic peripheral stem cell&#xD;
      transplantation in treating patients who have stage IV breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the ability of T-cell-depleted allogeneic blood stem cell transplantation&#xD;
           after an immunoablative conditioning regimen to induce a state of mixed host/donor&#xD;
           chimerism in patients with metastatic breast cancer.&#xD;
&#xD;
        -  Determine the ability of this treatment regimen to induce an allogeneic&#xD;
           graft-versus-tumor response in these patients.&#xD;
&#xD;
        -  Determine the feasibility of giving other approved therapies to these patients at the&#xD;
           first sign of disease progression in order to stabilize or produce a minimal or partial&#xD;
           response.&#xD;
&#xD;
      OUTLINE: Patients receive chemotherapy comprising fludarabine IV over 30 minutes and&#xD;
      cyclophosphamide IV over 1 hour on days 1-4. Patients receive filgrastim (G-CSF) SC daily&#xD;
      beginning on day 5 and continuing until blood counts recover. Treatment repeats every 21 days&#xD;
      for a maximum of 2 courses.&#xD;
&#xD;
      Patients receive a transplantation preparative regimen comprising fludarabine IV over 30&#xD;
      minutes and cyclophosphamide IV over 2 hours on days -6 to -3 (beginning on day 22 of&#xD;
      immune-depleting chemotherapy) followed by allogeneic peripheral blood stem cell&#xD;
      transplantation IV on day 0. Patients receive G-CSF SC daily beginning on day 0 and&#xD;
      continuing until blood counts recover, plus cyclosporine IV over 1-2 hours every 12 hours on&#xD;
      days -1 to 14 and then orally until day 40.&#xD;
&#xD;
      Patients with persistent malignant disease and less than grade II acute graft-versus-host&#xD;
      disease receive donor lymphocytes IV on days 42, 70, and 98.&#xD;
&#xD;
      Patients are followed twice weekly until day 100, and then at 6, 9, 12, 18, and 24 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 70 patients will be accrued for this study within 24 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2000</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic allogeneic lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Stage IV breast cancer&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Progressive disease&#xD;
&#xD;
               -  Increase in disease mass or less than partial response to therapy&#xD;
&#xD;
               -  At least one prior chemotherapy regimen for metastatic disease and progressed&#xD;
&#xD;
                    -  Must have received prior therapy with a taxane and an anthracycline&#xD;
&#xD;
          -  Estrogen/progesterone receptor-positive patients must have received and progressed on&#xD;
             at least one hormonal agent in adjuvant or metastatic setting&#xD;
&#xD;
          -  Her2-neu-expressing patients must have received and progressed on trastuzumab&#xD;
             (Herceptin®) in adjuvant or metastatic setting&#xD;
&#xD;
          -  Prior autologous stem cell transplantation allowed if less than complete response or&#xD;
             disease progression in adjuvant or metastatic setting&#xD;
&#xD;
          -  Consenting first-degree relative with at least 5 out of 6 HLA-antigen match (may&#xD;
             include mismatch at the D locus)&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Estrogen receptor status known&#xD;
&#xD;
               -  Progesterone receptor status known&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 to 70&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 80-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 6 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin ≤ 2 mg/dL&#xD;
&#xD;
          -  SGOT &lt; 4 times upper limit of normal&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  Hepatitis C antibody negative&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
          -  Creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  Left ventricular ejection fraction &gt; 45%&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  DLCO ≥ 50% of predicted&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior stem cell transplantation&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent steroids&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael R. Bishop, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NCI - Center for Cancer Research</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bishop MR. Nonmyeloablative allogeneic hematopoietic stem cell transplantation for metastatic breast cancer. Clin Breast Cancer. 2003 Apr;4(1):39-45. Review.</citation>
    <PMID>12744757</PMID>
  </reference>
  <results_reference>
    <citation>Bishop MR, Fowler DH, Marchigiani D, Castro K, Kasten-Sportes C, Steinberg SM, Gea-Banacloche JC, Dean R, Chow CK, Carter C, Read EJ, Leitman S, Gress R. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J Clin Oncol. 2004 Oct 1;22(19):3886-92. Epub 2004 Aug 16.</citation>
    <PMID>15314059</PMID>
  </results_reference>
  <results_reference>
    <citation>Bishop MR, Steinberg SM, Gress RE, Hardy NM, Marchigiani D, Kasten-Sportes C, Dean R, Pavletic SZ, Gea-Banacloche J, Castro K, Hakim F, Krumlauf M, Read EJ, Carter C, Leitman SF, Fowler DH. Targeted pretransplant host lymphocyte depletion prior to T-cell depleted reduced-intensity allogeneic stem cell transplantation. Br J Haematol. 2004 Sep;126(6):837-43.</citation>
    <PMID>15352988</PMID>
  </results_reference>
  <results_reference>
    <citation>Bishop MR, Kasten-Sportes C, Dean R, et al.: Preemptive DLI after T cell-depleted reduced-intensity allogeneic HSCT for metastatic breast cancer: effect on engraftment, GVHD, and anti-tumor response. [Abstract] Blood 102 (11): A- 5567, 2003.</citation>
  </results_reference>
  <results_reference>
    <citation>Bishop MR, Marchigiani D, Grasmeder S, et al.: Demonstration of clinical responses to adoptive cellular therapy using allogeneic T cells in metastatic breast cancer. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-657, 2003.</citation>
  </results_reference>
  <results_reference>
    <citation>Bishop MR, Marchigiani D, Odom J, et al.: Contribution of T cells to engraftment: a comparison of T cell depleted vs. T cell replete allografts after reduced-intensity conditioning. [Abstract] Blood 102 (11): A-2447, 2003.</citation>
  </results_reference>
  <verification_date>November 2004</verification_date>
  <study_first_submitted>July 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2013</last_update_posted>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>male breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

